

## Supplementary information

### **Radioactive hybrid semiconducting polymer nanoparticles for imaging-guided tri-modal therapy of breast cancer**

Junhao Gu,<sup>‡a</sup> Danling Cheng,<sup>‡a</sup> Haiyan Li,<sup>‡b</sup> Tao Yu,<sup>a</sup> Zhenghe Zhang,<sup>a</sup> Yue Liu,<sup>a</sup> Xiaoying Wang,<sup>\*c</sup> Xia Lu<sup>\*b</sup> and Jingchao Li<sup>\*a</sup>

<sup>a</sup> *State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai 201620, P. R. China*

<sup>b</sup> *Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou 225001, P. R. China*

<sup>c</sup> *Office of Hospital Infection and Disease Control and Prevention, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P. R. China*


<sup>‡</sup> *Contributed equally to this work.*

*\*Corresponding authors:*


*goodwxyz@163.com (X. Wang); lxgf2222@163.com (X. Lu); jcli@dhu.edu.cn (J. Li)*

**Table S1.** Hydrodynamic diameters of SPN<sub>H</sub> at the different feeding weights of PCPDTBT, PFODBT and F127.


Feeding weight of PCPDTBT, PFODBT and F127	Hydrodynamic diameter (nm)
1:1:20	110 ± 1.7
1:1:50	111.7 ± 5.0
1:1:100	119.5 ± 2.2
1:1:200	62.1 ± 1.5




**Fig. S1.** PDI of SPN<sub>H</sub> measured in different solutions (water, PBS and DMEM cell culture medium) at various days (n = 5).




**Fig. S2.** Radiolabeling stability of SPN<sub>H</sub> in different solution systems for various time (n = 3).




**Fig. S3.** Thermal images of aqueous solutions containing SPN<sub>H</sub> at various SP concentrations (12.5, 25, 50 and 100 µg/mL) under 808 nm laser irradiation (1 W/cm<sup>2</sup>) for 360 s.




**Fig. S4.** Fluorescence intensities of SOSG solutions containing  $\text{SPN}_\text{H}$  under different treatments: (a)  $\text{SPN}_\text{H}$  + US, (b)  $\text{SPN}_\text{H}$  + laser, and (c)  $\text{SPN}_\text{H}$  + US + laser.




**Fig. S5.** Cell viability analysis of 4T1 cells in PBS,  $\text{SPN}_\text{H}$ ,  $\text{SPN}_\text{H}$  + laser + NAC,  $\text{SPN}_\text{H}$  + laser (< 43 °C) and  $\text{SPN}_\text{H}$  + laser groups (n = 5).




**Fig. S6.** Ex vivo SPECT imaging of heart, liver, spleen, lung, kidney and tumor separated from  $\text{SPN}_\text{H}$ -injected tumor-bearing mice.




**Fig. S7.** Pharmacokinetic analysis of SPN<sub>H</sub> in mice (n = 3).



**Fig. S8.** (a) Fluorescence images of the produced  $^1\text{O}_2$  in 4T1 subcutaneous tumors in each group. (b) Green fluorescence intensity (FI) of produced  $^1\text{O}_2$  in 4T1 subcutaneous tumors (n = 3).



**Fig. S9.** The body weights of mice in various treatment groups (n = 5).



**Fig. S10.** H&E staining images of heart, spleen and kidney of mice in PBS and SPN<sub>H</sub> + US + laser groups.